Silexion Therapeutics ( ($SLXN) ) has provided an update. On May 22, 2025, Silexion Therapeutics Corp, a Cayman Islands exempted company, received ...

Silexion’s new groundbreaking study explores the potential impact of its next generation RNAI therapeutic candidate beyond pancreatic cancer aiming to address critical unmet needs in additional ...

Significant advancements in preclinical pipeline for SIL204, with groundbreaking data demonstrating efficacy against both ...

Silexion Therapeutics Corp has completed a significant preclinical study evaluating its RNA interference therapeutic candidate, SIL204, for various KRAS-driven cancers, including colorectal and ...

The precision oncology landscape is experiencing a potential breakthrough with Silexion Therapeutics' innovative approach to addressing KRAS-driven cancers. KRAS mutations represent one of the ...

GRAND CAYMAN, Cayman Islands, May 21, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech company developing RNA ...

"Completing this expanded preclinical evaluation represents an important milestone in our SIL204 development program," said Ilan Hadar, Chairman and CEO of Silexion Therapeutics. "While our initial ...

Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations ...

Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotech company developing RNA interference (RNAi) ...

This article was originally published on Quiver News, read the full story. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of ...

Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a ...